Societe Generale’s Alnylam Pharmaceuticals ALNY Stock Holding History

Societe Generale’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$353K	Buy	+6,353	New	+$400K	﹤0.01%	1869

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Societe Generale's ALNY Position: Q2 2016 in Review

Societe Generale opened a new position in Alnylam Pharmaceuticals (ALNY) in Q2 2016: 6,353 shares worth $353K. The stake represents ﹤0.01% of the portfolio and ranks #1869 among its holdings.

248 funds tracked by Wall St. Rank hold ALNY as of Q2 2016.

Societe Generale held 6,353 shares of Alnylam Pharmaceuticals worth $353K as of Q2 2016.
Alnylam Pharmaceuticals was a new Societe Generale position in Q2 2016.
Alnylam Pharmaceuticals made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1869 holding.
248 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.